Dostarlimab: A Review of Its Pharmacology and Clinical Use in Management of Cancer
Published: 2022-10-11
Page: 108-113
Issue: 2022 - Volume 5 [Issue 2]
Busayo Odunayo Akodu *
Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Jos, Plateau State, Nigeria.
Azike Ruth Chinazor
Department of Chemistry, Faculty of Natural Sciences, University of Jos, Nigeria.
Ikalo David Oseghale
Department of Biochemistry, Faculty of Life Sciences, University of Benin, Nigeria.
Regina Titilayo Oddiri
Department of Biochemistry, Lagos State University, Lagos State, Nigeria.
George Chigozie Njoku
Department of Biochemistry, College of Natural Sciences, Michael Okpara University of Agriculture, Nigeria.
Godwin Okoye
University of Maryland School of Pharmacy, Baltimore MD, US State.
*Author to whom correspondence should be addressed.
Abstract
According to the World Health Organization, cancer is the biggest cause of mortality globally, accounting for almost 10 million deaths in 2020, or nearly one in every six deaths (WHO). Breast (2.26 million instances), lung (2.21 million cases), colon and rectum (1.93 million cases), and prostate cancers will be the most frequent cancers in 2020 (1.41 million Cases).
A PD-1 monoclonal antibody called dostarlimab (JEMPERLI) has been found to be effective in treatment of patients with rectal cancer, who have advanced or recurrent disease that is mismatch repair deficient (dMMR) and who have progressed during or after prior treatment with a platinum-containing regimen. This indication was quickly approved based on the rate of tumor response and the length of the response, both of which were determined using an FDA-approved test. In this review, we provide simple and comprehensible pharmacodynamic and Pharmacokinetic details of the drug to the healthcare community as we believe it would serve as quick point of reference in cases of emergency information search.
Keywords: Dostarlimab, cancer, immunotherapy, tumour, monoclonal antibody